Introduction
Genital herpes: past, present and future Genital herpes is the most widespread sexually transmitted disease in the Western world with approximately 25-35% of sexually active adults being infected (Johnson et al., 1989; Christenson et al., 1990) . Herpes simplex virus type 2 (HSV-2) is the main causative agent of genital herpes, although HSV-1 is increasingly giving rise to genital episodes. In most patients, symptoms are most severe during the primary infection and may include considerable pain and severe constitutional symptoms. Following resolution of the primary infection, a latent infection is established in the nerve ganglia and may be reactivated, resulting in further recurrent episodes. These are generally less severe than the primary infection but may give rise to considerable discomfort, especially if they are very frequent.
Clinical presentations of genital herpes can vary considerably between patients and between episodes. Infections may involve mucous membranes, the skin and/or the nervous system, giving rise to distinctive types of lesions. Primary infections are generally much more severe than later episodes. However, some patients who present with apparent primary lesions are seropositive, to either one or both of the two HSV subtypes, and are hence experiencing a non-primary first episode. In many patients, recurrences are largely asymptomatic and the patient may be totally unaware of the episode. This has important implications, as patients are likely to be shedding virus and are therefore at risk of transmitting the disease, even though they are unaware of the lesions. Antiviral therapy has an important role to play in the management ofgenital herpes. For patients presenting with severe primary infections or non-primary first episodes, antiviral therapy can reduce the duration and severity of symptoms. It is therefore appropriate to offer antiviral therapy. Antiviral therapy may also have an impact on recurrences and should be started by the patient at the first sign of symptoms. However, the benefit of such episodic treatment is often modest and should probably be replaced by chronic suppressive therapy in patients who suffer from frequent and/or severe recurrences. Suppressive therapy not only reduces the frequency of episodes, the occurrence of prodromal symptoms and neuralgia, but also reduces viral shedding and hence the risk of transmission. A fol-© 1997 International Medical Press Ltd lowing article discusses the role of antiviral therapy in the management of genital herpes.
Of particular interest is recent research which is suggesting that antiviral treatment of primary infections may be able to change the course of the infection by preventing the establishment of latency. Animal studies reported in this supplement by Field and Thackray indicate that administration offamciclovir during the primary infection can reduce the number of ganglia latently infected with HSV-1 or HSV-2. Valaciclovir was found to be markedly less effective.These results are supported by clinical observations of patients treated for primary episodes of genital herpes with either aciclovir or famciclovir (Woolley P. 8th
European Congress if Clinical Microbiology and Inftctious
Diseases, Lausanne, Switzerland; 25-28 May 1997) . A higher percentage of the patients who received aciclovir returned to the clinic with recurrences within 6 months of receiving treatment, compared with those treated with famciclovir.These preliminary observations are now being followed-up in a multicentre clinical study comparing famciclovir with valaciclovir for the treatment of first episode genital herpes. The results of this study should clarify whether these new antiviral agents can impact on the development oflatency.
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